FY2026 EPS Estimates for Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Lowered by Analyst

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRXGet Rating) – Equities researchers at Diamond Equity lowered their FY2026 earnings per share estimates for shares of Salarius Pharmaceuticals in a research report issued on Thursday, August 11th. Diamond Equity analyst H. Diamond now forecasts that the company will post earnings of ($0.01) per share for the year, down from their prior estimate of $0.01. The consensus estimate for Salarius Pharmaceuticals’ current full-year earnings is ($0.44) per share.

Salarius Pharmaceuticals (NASDAQ:SLRXGet Rating) last announced its quarterly earnings data on Friday, August 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. During the same period in the prior year, the company earned ($0.07) EPS.

Salarius Pharmaceuticals Trading Up 2.2 %

Shares of NASDAQ:SLRX opened at $0.23 on Monday. Salarius Pharmaceuticals has a 12-month low of $0.16 and a 12-month high of $1.20. The company has a market cap of $12.91 million, a PE ratio of -0.59 and a beta of 1.13. The stock has a 50 day moving average of $0.21 and a 200 day moving average of $0.29.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Salarius Pharmaceuticals stock. Millennium Management LLC boosted its holdings in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRXGet Rating) by 1,350.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 291,900 shares of the company’s stock after purchasing an additional 271,772 shares during the quarter. Millennium Management LLC owned approximately 0.52% of Salarius Pharmaceuticals worth $61,000 as of its most recent SEC filing. Institutional investors own 11.38% of the company’s stock.

Salarius Pharmaceuticals Company Profile

(Get Rating)

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.

Featured Articles

Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.